PMID- 30883406
OWN - NLM
STAT- MEDLINE
DCOM- 20201105
LR  - 20230911
IS  - 1538-943X (Electronic)
IS  - 1058-2916 (Print)
IS  - 1058-2916 (Linking)
VI  - 66
IP  - 3
DP  - 2020 Mar
TI  - Correlation Among Antifactor Xa, Activated Partial Thromboplastin Time, and 
      Heparin Dose and Association with Pediatric Extracorporeal Membrane Oxygenation 
      Complications.
PG  - 307-313
LID - 10.1097/MAT.0000000000000986 [doi]
AB  - Anticoagulation is essential during extracorporeal membrane oxygenation (ECMO) to 
      prevent catastrophic circuit clotting. Several assays exist to monitor 
      unfractionated heparin (UFH), the most commonly used anticoagulant during ECMO, 
      but no single test or combination of tests has consistently been proven to be 
      superior. This retrospective observational study examines the correlation among 
      antifactor Xa level, activated partial thromboplastin time (aPTT), and UFH dose 
      and the association between antifactor Xa level and aPTT with survival and 
      hemorrhagic and thrombotic complications. Sixty-nine consecutive neonatal and 
      pediatric ECMO patients from September 2012 to December 2014 at a single 
      institution were included. Spearman rank correlation was used to compare 
      antifactor Xa level, aPTT, and UFH dose. Significant but poor correlation exists 
      between antifactor Xa level and UFH dose rho = 0.1 (p < 0.0001) and aPTT and UFH 
      dose rho = 0.26 (p < 0.0001). Antifactor Xa level and aPTT were weakly correlated 
      to each other rho = 0.38 (p < 0.0001). In an univariate analysis, there was no 
      difference between survival and antifactor Xa level, aPTT, or UFH dose. Multiple 
      anticoagulation tests may be superior to a single test during ECMO.
FAU - McMichael, Ali B V
AU  - McMichael ABV
AD  - From the Department of Pediatrics, UT Southwestern, Dallas, Texas.
FAU - Hornik, Christoph P
AU  - Hornik CP
AD  - Department of Pediatrics, Duke University Hospital, Durham, North Carolina.
AD  - Duke Clinical Research Institute, Durham, North Carolina.
FAU - Hupp, Susan R
AU  - Hupp SR
AD  - From the Department of Pediatrics, UT Southwestern, Dallas, Texas.
FAU - Gordon, Sharon E
AU  - Gordon SE
AD  - Department of Pharmacy, Children's Hospital Colorado, Aurora, Colorado.
FAU - Ozment, Caroline P
AU  - Ozment CP
AD  - Department of Pediatrics, Duke University Hospital, Durham, North Carolina.
LA  - eng
GR  - HHSN267200700051C/HD/NICHD NIH HHS/United States
GR  - UL1 TR001117/TR/NCATS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - ASAIO J
JT  - ASAIO journal (American Society for Artificial Internal Organs : 1992)
JID - 9204109
RN  - 0 (Anticoagulants)
RN  - 0 (Factor Xa Inhibitors)
RN  - 9005-49-6 (Heparin)
SB  - IM
MH  - Adolescent
MH  - Anticoagulants/*administration & dosage
MH  - Child
MH  - Child, Preschool
MH  - Extracorporeal Membrane Oxygenation/*adverse effects
MH  - Factor Xa Inhibitors/*blood
MH  - Female
MH  - Heparin/*administration & dosage
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - Male
MH  - *Partial Thromboplastin Time
MH  - Retrospective Studies
PMC - PMC10492630
MID - NIHMS1869195
EDAT- 2019/03/19 06:00
MHDA- 2020/11/06 06:00
PMCR- 2023/09/09
CRDT- 2019/03/19 06:00
PHST- 2019/03/19 06:00 [pubmed]
PHST- 2020/11/06 06:00 [medline]
PHST- 2019/03/19 06:00 [entrez]
PHST- 2023/09/09 00:00 [pmc-release]
AID - 00002480-202003000-00012 [pii]
AID - 10.1097/MAT.0000000000000986 [doi]
PST - ppublish
SO  - ASAIO J. 2020 Mar;66(3):307-313. doi: 10.1097/MAT.0000000000000986.